This is a working overview of HPLC-UV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Most tropical cyclones form on the side of the subtropical ridge closer to the equator, then move poleward past the ridge axis before recurving into the main belt of the Westerlies. Areas west of Japan and Korea tend to experience many fewer September–November tropical cyclone impacts during El Niño and neutral years. During El Niño years, the break in the subtropical ridge tends to lie near 130°E, which would favor the Japanese archipelago.
== Modern dating methods == Radiometric dating has been carried out since 1905 when it was invented by Ernest Rutherford as a method by which one might determine the age of the Earth. In the century since then the techniques have been greatly improved and expanded. Dating can now be performed on samples as small as a nanogram using a mass spectrometer. The mass spectrometer was invented in the 1940s and began to be used in radiometric dating in the 1950s. It operates by generating a beam of ionized atoms from the sample under test. The ions then travel through a magnetic field, which diverts them into different sampling sensors, known as "Faraday cups," depending on their mass and level of ionization. On impact in the cups, the ions set up a very weak current that can be measured to determine the rate of impacts and the relative concentrations of different atoms in the beams.
Natriuretic peptides comprise a family of 3 structurally related molecules: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), encoded by a gene symbolized NPPC. These peptides possess potent natriuretic, diuretic, and vasodilating activities and are implicated in body fluid homeostasis and blood pressure control. Unlike ANP and BNP, CNP does not have direct natriuretic activity. This is because CNP is a selective agonist for the B-type natriuretic receptor (NPRB) whereas ANP and BNP are selective for the A-type natriuretic receptor (NPRA). It is synthesized and secreted from the endothelium in response to many stimuli, for example shear stress, similar to nitric oxide (NO), and certain proinflammatory cytokines.
Glycylglycine is the dipeptide of glycine, making it the simplest peptide. The compound was first synthesized by Emil Fischer and Ernest Fourneau in 1901 by boiling 2,5-diketopiperazine (glycine anhydride) with hydrochloric acid. Shaking with alkali and other synthesis methods have been reported. Because of its low toxicity, it is useful as a buffer for biological systems with effective ranges between pH 2.5–3.8 and 7.5–8.9; however, it is only moderately stable for storage once dissolved. It is used in the synthesis of more complex peptides. Glycylglycine has also been reported to be helpful in solubilizing recombinant proteins in E. coli. Using different concentrations of the glycylglycine improvement in protein solubility after cell lysis has been observed.
Sources: en.wikipedia.org
== Mode of action == The toxin binding site on the channels has high affinity for the toxins when they are closed and low affinity when channels are activated. As a result, the toxin preferentially binds to the closed channels. It binds at a region which contains the voltage-sensing domains. When bound, the toxin makes it more difficult for channels to be opened by depolarization, so much larger depolarizations are required for channel activation. Grammotoxin also binds to potassium channels but with lower affinity than to the calcium channels.
Lee (1992), former Associated Press bureau chief in Pyongyang and Seoul Jori Finkel (1992), art reporter for The New York Times and Los Angeles Times Olivier Knox (1992), chief Washington correspondent for SiriusXM and former president of the White House Correspondents' Association Jim Frederick (1993), author and journalist Russell Gold (1993), journalist for The Wall Street Journal and Pulitzer Prize-finalist Michael Rothfeld (1993), journalist for The Wall Street Journal and winner of the 2019 Pulitzer Prize for National Reporting Brad Stone (1993), journalist for Bloomberg Business Anne Kornblut (1994), correspondent for The Washington Post, winner of the 2014 Pulitzer Prize for Public Service Joshua Prager (1994), journalist and author who writes on historical secrets Jodi Kantor (1996), writer and former editor on culture and politics for The New York Times, winner of the 2018 Pulitzer Prize for Public Service Harriet Ryan (1996), journalist and winner of the 2019 Pulitzer Prize for Investigative Reporting Robin Shulman (1996), freelance journalist Kate Kelly (1997), journalist for The New York Times Nicholas Kulish (1997), Berlin bureau chief for The New York Times and novelist Patrick Radden Keefe (1999), writer and investigative journalist David Epstein (2002), investigative reporter at ProPublica and author of the New York Times bestseller The Sports Gene Nick Schifrin (2002), Al Jazeera America's Middle East correspondent Ben Casselman (2003), economics reporter at The New York Times Jonah Lehrer (2003), former writer for The New Yorker discharged for falsifying quotes Poppy Harlow (2005), correspondent for CNN Sarah Maslin Nir (2005), investigative journalist for The New York Times Marc Tracy (2007), journalist for The New York Times, recipient of a 2011 National Magazine Award and a 2012 National Jewish Book Award Linette Lopez (2008), journalist for Business Insider involved in the December 15, 2022 Twitter suspensions Nellie Bowles (2010), technology journalist for The New York Times Cecilia Reyes (2015), winner of the Pulitzer Prize for Investigative Reporting in 2022
== References == 11. Website publication of Silver Book: The Silver Book and the NPU Format for Clinical Laboratory Science Reports Regarding Properties, Units, and Symbols . Published Online: 2017-04-25; Published in Print: 2017-04-25
== Physiologic effects == BNP decreases sodium reabsorption in the distal convoluted tubule (interaction with NCC) and cortical collecting duct of the nephron via guanosine 3',5'-cyclic monophosphate (cGMP) dependent phosphorylation of ENaC.
=== Thermal-induced phase separation === Thermal-induced phase separation separates a homogenous polymer solution into a multi-phase system via thermodynamic changes. The procedure involves five steps: polymer dissolution, liquid-liquid or liquid-solid phase separation, polymer gelation, extraction of solvent from the gel with water, and freezing and freeze-drying under vacuum. Thermal-induced phase separation method is widely used to generate scaffolds for tissue regeneration. The homogenous polymer solution in the first step is thermodynamically unstable and tends to separate into polymer-rich and polymer-lean phases under appropriate temperature. Eventually after solvent removal, the polymer-rich phase solidifies to form the matrix and the polymer-lean phase develops into pores. Next, two types of phase separation can be carried out on the polymer solution depending on the desired pattern. Liquid-liquid separation is usually used to form bicontinuous phase structures while solid-liquid phase separation is used to form crystal structures. The gelation step plays a crucial role in controlling the porous morphology of the nanofibrous matrices. Gelation is influenced by temperature, polymer concentration, and solvent properties. Temperature regulates the structure of the fiber network: low gelation temperature results in formation of nanoscale fiber networks while high gelation temperature leads to the formation of a platelet-like structure.
Sources: en.wikipedia.org
Wrinkles deepen, and forehead frown lines can be seen even when not frowning. Telangiectasias (spider veins) are most commonly seen around the nose, cheeks, and chin. Skin becomes leathery, and laxity occurs. Solar lentigines (age spots) appear on the face and hands. Possibly pre-cancerous red and scaly spots (actinic keratoses) appear. Cutaneous malignancies In addition to the above symptoms, photoaging can also result in an orderly maturation of keratinocytes and an increase in the cell population of the dermis, where abundant, hyperplastic, elongated, and collapsed fibroblasts and inflammatory infiltrates are found. Photodamage can also be characterized as a disorganization of the collagen fibrils that constitute most of the connective tissue, and the accumulation of abnormal, amorphous, elastin-containing material, a condition known as actinic elastosis.
238U(22Ne,xn)260−xNo (x=4,5,6) This reaction was first studied in 1964 at FLNR. The team were able to detect decays from 252Fm and 250Fm. The 252Fm activity was associated with an ~8 s half-life and assigned to 256102 from the 4n channel, with a yield of 45 nb. They were also able to detect a 10 s spontaneous fission activity also tentatively assigned to 256102. Further work in 1966 on the reaction examined the detection of 250Fm decay using chemical separation and a parent activity with a half-life of ~50 s was reported and correctly assigned to 254102. They also detected a 10 s spontaneous fission activity tentatively assigned to 256102. The reaction was used in 1969 to study some initial chemistry of nobelium at the FLNR. They determined eka-ytterbium properties, consistent with nobelium as the heavier homologue. In 1970, they were able to study the SF properties of 256No. In 2002, Patin et al. reported the synthesis of 256No from the 4n channel but were unable to detect 257No. The cross section values for the 4-6n channels have also been studied at the FLNR.
=== In Europe === Chia is considered a novel food in Europe because it does not have "a significant history of consumption within the European Union before 15 May 1997", according to the Advisory Committee of Novel Foods and Processes. Under this rule, chia seeds may be 5% of total matter in bread products. Prepackaged chia seeds must carry additional labelling to inform the consumer that the daily intake is no more than 15 grams and pure chia oil only 2 grams daily. Chia seeds sold in the EU are imported mainly from South American and Central American countries and require inspections for levels of pesticides, contaminants, and microbiological criteria.
=== Ecuador === Once Bonpland recovered, the expedition departed for Quito via the difficult Quindiu Pass, navigating steep terrain, dense forests, and swamps. They refused to use local indigenous porters, the silleros carrying their own provisions for the journey. From Cartago, the route continued south to Popayán, where they conducted scientific excursions, including a visit to the volcano of Puracé. Next, they crossed the harsh Paramos of Pasto, a cold, desolate plateau marked by volcanic activity and frequent mists. The road was dangerous and strewn with animal bones. The travelers endured harsh conditions, sheltering under makeshift tents, and spent Christmas in Pasto before finally reaching Quito in early January. In Quito, Humboldt described the city as attractive but cold and prone to earthquakes, noting the effects of the 1797 disaster. Despite frequent tremors, the residents were lively and pleasure-seeking. Humboldt spent six months in Quito, socializing with prominent families, especially the Marqués de Selvalegre’s. He formed a close bond with Carlos Montúfar, who joined his later travels. Humboldt dedicated much of his time to studying the region’s volcanoes, including Pichincha, Cotopaxi, Antisana, Tungurahua, Iliniza, and Chimborazo. Mountaineering was rare, and Humboldt developed his techniques through experience and acclimatization. His first attempt to climb Pichincha ended in physical distress, but he persevered, eventually reaching significant heights and conducting scientific observations.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.